Astellas cuts a bispecific in cancer and a mitochondria-focused asset from Mitobridge dealnews2024-04-25T13:43:49+00:00April 25th, 2024|Endpoints News|
Merck KGaA to expand German headquarters with €300M+ research center news2024-04-25T13:08:33+00:00April 25th, 2024|Endpoints News|
AstraZeneca’s Pascal Soriot says new rise in pay is ‘really about’ potential successornews2024-04-25T11:16:56+00:00April 25th, 2024|Endpoints News|
Regeneron and Mammoth strike $100M deal to pair tiny CRISPR editors with new delivery ideanews2024-04-25T11:00:27+00:00April 25th, 2024|Endpoints News|
Bristol Myers plans $1.5B in cost cuts as CEO promises more ‘agile’ companynews2024-04-25T10:59:21+00:00April 25th, 2024|Endpoints News|
Sanofi spotlights early-stage cancer assets, counts on grandfather clause on Biosecurenews2024-04-25T09:12:13+00:00April 25th, 2024|Endpoints News|
Astellas’ Friedreich’s ataxia gene therapy cleared for clinical study after earlier version stumblednews2024-04-25T06:00:16+00:00April 25th, 2024|Endpoints News|
Walgreens will build out specialty pharmacy business, leaning into drug and therapy servicesnews2024-04-25T04:01:41+00:00April 25th, 2024|Endpoints News|
BioMarin’s Roctavian struggles continue. Is a divestment in the future?news2024-04-25T02:46:42+00:00April 25th, 2024|Endpoints News|
Cidara buys back flu rights, sells antifungal and inks $240M PIPEnews2024-04-24T20:05:09+00:00April 24th, 2024|Endpoints News|